Microbix Biosystems Inc.

268 articles with Microbix Biosystems Inc.

• Microbix Makes Early Repayment of 9% Interest Debenture

  10/4/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has completed the early repayment of a debenture series on which it owed C$ 1.3 million and was paying an interest rate of 9.0%.

• Microbix Presenting Product Results at AACCQAPs to Support Testing for COVID Viral Variants

  9/27/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products at “AACC” the annual scientific meeting & clinical laboratory exposition of the American Association of Clinical Chemistry, taking place in live and virtual formats from Atlanta, GA, September 26-30, 2021.

• Microbix Presenting at Muskoka Capital Conference Meetings with Growth-Oriented Investors, September 24-26, 2021

  9/23/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, ON, September 24-26, 2021.

• Microbix Reports Record Results for Q3 Fiscal 2021Record Sales of $5.5 million, Record Net Earnings of $1.5 million

  8/12/2021

  Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2021 ending June 30, 2021 (“ Q3 ” and “ YTD ”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from innovative, proprietary, and branded medical devices.

• Microbix Presenting Product Results to Industry

  7/8/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products at “ECCMID 2021” the 31st annual congress organized by the European Society of Clinical Microbiology and Infectious Diseases, taking place in virtual format July 9-12, 2021.

• Microbix Announces Quality Products Distribution AgreementAppointment of Thomas Scientific as U.S. Distributor

  7/7/2021

  Microbix Biosystems Inc. announces the appointment of Thomas Scientific LLC as distributor of Microbix’s quality assessment products (QAPs™) for the United States.

• Microbix Secures Third Ontario Manufacturing SiteLeasing and Equipping 10,000 Square Foot Building Adjacent to Current Sites

  6/3/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has secured a third manufacturing site in Mississauga, Ontario, by way of a long-term lease agreement for a property adjacent to its two current sites.

• Microbix Announces Quality Products Distribution AgreementAppointment of SDT Molecular of Singapore

  5/31/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces the appointment of SDT Molecular Pte Ltd as distributor of Microbix’s quality assessment products for four Asia-Pacific territories.

• Microbix Reports Record Results for Q2 Fiscal 2021Record Q2 Sales of $4.35 million, Record Net Earnings of $0.8 million

  5/13/2021

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2021 ending March 31, 2021 (“Q2” and “H1”), with record sales and earnings, plus progress upon its strategic goals.

• Microbix & SpeeDx Form Exclusive CollaborationFocus on Diagnostics and Controls for Anti-Microbial Resistant Infections

  4/26/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, and SpeeDx Pty. Ltd., a developer of innovative molecular diagnostics solutions, are pleased to announce the formation of a collaboration under which Microbix will be exclusive developer of Quality Assessment Products to facilitate the registration and commercialization of SpeeDx diagnostic assays.

• Microbix Receives $4.25 Million Order For Viral Transport MediumAn Initial Order From Government Of Ontario Procurement Authorities

  4/23/2021

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has received an initial order of CDN$ 4.25 million for its viral transport medium (generically known as “VTM” and branded as “DxTM™” by Microbix). DxTM is a test sample-collection device that is essential for PCR-testing for the virus causing COVID-19 disease.

• Microbix to Present at Bloom Burton Investor ConferenceVirtual Healthcare Investor Conference on April 20 & 21

  4/19/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that its CEO, Cameron Groome, has been invited to present at the 2021 Bloom Burton & Co. Healthcare Investor Conference, being held virtually from Toronto, Ontario, Canada, on April 20 and 21, 2021.

• Microbix Announces Annual and Special Meeting Voting Results - Mar 31, 2021

  3/31/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company which was held on March 30, 2021.

• Microbix & Seegene Canada Form COVID-Variant CollaborationFocus on Supporting Canadian Labs with Variant-related Assays and QAPs

  3/15/2021

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene®), a provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce a collaboration under which Seegene will distribute and recommend Microbix’s new COVID-variant Quality Assessment Products

• Microbix Antigen-test QAPs Now Available For Clinical UseREDxFLOQ SARS-CoV-2 Antigen as IVD Controls in Canada, the EU, and the U.S.

  3/11/2021

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability of more of its Quality Assessment Products (QAPs™) as In-Vitro Diagnostic “IVD” Controls – to monitor the workflow accuracy of antigen-based tests for the virus causing COVID-19 disease in Canada, the EU, and the United States.

• Microbix Announces Issuance of Stock Options Using Shareholder-Approved Plan to Incentivize and Retain

  2/18/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Announces Quality Products Distribution Agreement

  2/16/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces an agreement with Oneworld Accuracy Inc. to distribute Microbix’s Quality Assessment Products on a non-exclusive basis across the continent of Africa, in Canada, and in the United States.

• Microbix Reports Results for Q1 Fiscal 2021Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth

  2/11/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, reports results for the first quarter of its fiscal 2021, the three-months ended December 31, 2020, with record sales and continued progress upon its strategic goals.

• Microbix Announces Material First Sales of Viral Transport MediumInitial Production of 50,000 Vials Entirely Sold

  2/9/2021

  Microbix Biosystems Inc., a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium that supports Canadian RT-PCR testing for the virus causing COVID-19 disease.

• Microbix Viral Transport Medium Now AvailableInitial Capacity of 50,000 Vials/Week under Health Canada Regulation

  1/28/2021

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the commercial availability of its viral transport medium (VTM) to support Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease.